The development of a 30-color immunophenotyping panel using the Cytek Aurora™ Spectral Flow Cytometer has enabled detailed profiling of T cell, NK and B cell subsets, along with their functional states.
Analysis of UGT1A1 pharmacogenomic profiles in 564 cancer patients revealed that 53% had reduced metabolizer status, potentially increasing toxicity or reducing efficacy of UGT1A1-metabolized drugs.
PacBio amplicon sequencing was used as an orthogonal method to confirm the performance of Labcorp Pan-Heme NGS (LPH) panel to detect somatic variants in hematologic malignancies across 141 clinically relevant genes.
Analysis of 146 Japanese pancreatic adenocarcinoma (PC) patients using exome-based cancer genomic profiling (CGP) identified somatic mutations with KRAS,TP53, SMAD4 and CDKN2A being the most frequent.
Analysis of syngeneic mouse models using human-validated immune gene expression (iGEX) measurements to assess tumor immune microenvironments and treatment responses demonstrated that in vivo tumor fragments exhibited higher immune activity than in vitro tumor cell lines and closely resembled iGEX measures in human tumors.
Evaluation of TLR3 RNA expression landscape in 514 real-world tumors with categorization into "High" or "Non-High" levels and analysis of associations with patient characteristics, immune markers and cancer subtypes, demonstrated a significant correlation between high TLR3 expression and other immune modulation targets such as VISTA and TIM3 RNA express
PGDx elio plasma focus Dx, a liquid biopsy next-generation sequencing (NGS) assay, detects 33 genes including difficult to detect structural variants with high sensitivity, specificity, accuracy and reproducibility.
Integrated comprehensive genomic profiling (CGP) of cfDNA with matched WBC analysis enhances the accuracy of molecular response (mR) in patients with metastatic non-small cell lung cancer (mNSCLC) receiving immunotherapy. Patients with mR had significantly longer overall survival, whereas early molecular progression strongly predicted poorer outcomes.
